The International Association for the Study of Lung Cancer (IASLC) recently announced it is naming the Translational Research Lectureship Award after longtime member and former IASLC Chief Executive Officer Fred R. Hirsch, MD, PhD. The award, which was previously named after Adi Gazdar, MD, who died in 2018, will be called the Fred R. Hirsch Lectureship Award for Translational Research. The IASLC board also voted to name the IASLC Merit Award for Dr. Gazdar, to reflect his lifelong contributions and legacy.
Fred R. Hirsch, MD, PhD
The IASLC conveys lectureship awards each year at its annual World Conference on Lung Cancer (WCLC) to celebrate individuals who are stars in the field of lung cancer and who have produced exemplary academic work and service to the IASLC, including the Translational Research Lectureship Award.
IASLC Growth Under Dr. Hirsch’s Leadership
Dr. Hirsch served in many capacities with IASLC and was named Chief Executive Officer in 2013. He led the growth of the IASLC staff from 5 to 23, doubled the numbers of members in IASLC during his tenure, strengthened the financial position of IASLC, and improved its peer-reviewed publication, Journal of Thoracic Oncology. The IASLC WCLC moved from every other year to an annual meeting under Dr. Hirsch’s time as Chief Executive Officer, culminating in record attendance and multiple practice-changing abstracts at his final WCLC as Chief Executive Officer, IASLC 19th WCLC in Toronto. He is currently Executive Director, Center for Thoracic Oncology, Tisch Cancer Institute, Mount Sinai Health; Professor of Medicine, Icahn School of Medicine; and the Joe Lowe and Louis Price Professor of Medicine and Associate Director, Tisch Cancer Institute.
The recipient of the award will be announced and recognized at the IASLC 2020 World Conference on Lung Cancer in Singapore, August 9–12, 2020. Visit www.iaslc.org for more information.
